


L1 HAS NO ANSWERS
L1 STR



REP G1=(0-1) CH
REP G2=(0-2) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 14 1 8
NUMBER OF NODES IS 19

STEREO ATTRIBUTES: NONE


=> d his 13

(FILE 'REGISTRY' ENTERED AT 15:14:06 ON 16 APR 2008)

L3 597 S L1 FUL

=> d 14

L4 HAS NO ANSWERS
L4 STR



REP G1=(0-1) CH
REP G2=(0-2) CH
NODE ATTRIBUTES:
DEFAULT MLEVEL IS ATOM
DEFAULT ECLEVEL IS LIMITED

GRAPH ATTRIBUTES:
RSPEC 14 1 8
NUMBER OF NODES IS 20

STEREO ATTRIBUTES: NONE

=> search 14

ENTER TYPE OF SEARCH (SSS), CSS, FAMILY, OR EXACT:sss
ENTER SCOPE OF SEARCH (SAMPLE), FULL, RANGE, OR SUBSET:subset

ENTER SUBSET L# OR (END):ful
 FUL IS NOT A VALID L#
 L-numbers must be in the range L1-L999.
 ENTER SUBSET L# OR (END):13
 ENTER SUBSET SEARCH SCOPE - SAMPLE, FULL, RANGE, OR (END):ful
 FULL SUBSET SEARCH INITIATED 15:18:54 FILE 'REGISTRY'
 FULL SUBSET SCREEN SEARCH COMPLETED - 597 TO ITERATE


100.0% PROCESSED 597 ITERATIONS 466 ANSWERS
 SEARCH TIME: 00.00.01

L5 466 SEA SUB=L3 SSS FUL L4

=> d scan

L5 466 ANSWERS REGISTRY COPYRIGHT 2008 ACS on STN
 IN 3(2H)-Pyridazinone, 6-[(3S,4S)-3-(5-chloro-2-pyridinyl)-4-[(3R,5S)-4-hydroxy-3,5-dimethyl-4-phenyl-1-piperidinyl]carbonyl]-1-pyrrolidinyl]-
 MF C27 H30 Cl N5 O3

Absolute stereochemistry.



PROPERTY DATA AVAILABLE IN THE 'PROP' FORMAT

HOW MANY MORE ANSWERS DO YOU WISH TO SCAN? (1):0

=> fil caplus

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	224.14	224.35

FILE 'CAPLUS' ENTERED AT 15:19:26 ON 16 APR 2008
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2008 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 16 Apr 2008 VOL 148 ISS 16
FILE LAST UPDATED: 15 Apr 2008 (20080415/ED)

Effective October 17, 2005, revised CAS Information Use Policies apply. They are available for your review at:

<http://www.cas.org/infopolicy.html>


=> s 15

L6 15 L5

=> d bib abs 1-15

L6 ANSWER 1 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2007:966651 CAPLUS
DN 147:322997
TI Preparation of piperidinoylazinylypyrrolidines as melanocortin type 4
receptor agonists
IN Andrews, Mark David; Brown, Alan Daniel; Lansdell, Mark Ian; Summerhill,
Nicholas William
PA Pfizer Limited, UK
SO PCT Int. Appl., 71pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007096763	A2	20070830	WO 2007-IB456	20070219
	WO 2007096763	A3	20071018		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SV, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
PRAI	US 2006-776295P	P	20060223		
	US 2007-887840P	P	20070202		
OS	MARPAT 147:322997				
GI					



AB Title compds. [I; 1 of X, Y = N, the other = CH; R = F, Cl, cyano, CF₃, MeO; R₁ = (substituted) Ph, 2-pyridyl, cycloalkyl, cycloalkylmethyl; R₂ = H, F, Cl; Het = (substituted) 6-membered (aromatic) ring containing 1-2 N atoms;

with provisos], were prepared Thus, 2-chloro-5-cyanopyridine, (3R,4R,5S)-1-[[(3S,4S)-4-(5-chloropyridin-2-yl)pyrrolidin-3-yl]carbonyl]-4-(4-fluorophenyl)-3,5-dimethylpiperidin-4-ol (preparation given), and ethyldiisopropylamine were heated together in MeCN at 70° overnight to give 77% 6-[(3S,4S)-3-(5-chloropyridin-2-yl)-4-[[(3R,4R,5S)-4-(4-fluorophenyl)-4-hydroxy-3,5-dimethylpiperidin-1-yl]carbonyl]pyrrolidin-1-yl]nicotinonitrile. The latter showed MC₄ agonist activity with EC₅₀ <0.52 nM.

L6 ANSWER 2 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:150961 CAPLUS

DN 146:229190

TI Preparation of pyrrolidinylcarbonylpiperidines as melanocortin subtype 4 (MC₄) receptor agonists for treatment of lower urinary tract dysfunction.

IN McMurray, Gordon; Phillips, Stephen Charles; Westbrook, Simon Lempriere

PA Pfizer Limited, UK

SO PCT Int. Appl., 85pp.


CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2007015157	A2	20070208	WO 2006-IB2119	20060720
	WO 2007015157	A3	20070518		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			
	CA 2615209	A1	20070208	CA 2006-2615209	20060720
PRAI	GB 2005-15817	A	20050801		
	US 2005-705237P	P	20050802		
	WO 2006-IB2119	W	20060720		
OS	MARPAT 146:229190				
GI					



AB Use of MC4 receptor antagonists, e.g. [I; R1 = (substituted) alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, aryl, heterocyclyl, etc.; R2 = H, OH, OMe; R3 = H, R1; R4, R5 = H, halo, alkyl, alkenyl, alkynyl, cyano, CF3, CH2CF3, OCF3, OCH2CF3, cycloalkenyl(alkyl), amino(alkyl), etc.; R4R5 = atoms to form fused 5-7 membered (unsatd.) ring] for the manufacture of a medicament for the treatment of lower urinary tract dysfunction is claimed. Thus, title compound (II) (preparation outlined) at 2 mg/kg i.v. in the dog urethral pressure model gave a 20% increase in peak urethral pressure.

L6 ANSWER 3 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:150182 CAPLUS

DN 146:229186

TI Preparation of piperidinoyl-pyrrolidine and piperidinoyl-piperidine compounds as MCR4 agonists

IN Andrews, Mark David; Brown, Alan Daniel; Fradet, David Sebastien; Lansdell, Mark Ian

PA Pfizer Limited, UK

SO PCT Int. Appl., 103pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2007015162	A1	20070208	WO 2006-IB2151	20060726
W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM			
PRAI US 2005-706191P	P	20050804		
OS MARPAT 146:229186				

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Title compds. I [n = 1, 2; R6 = H, alkyl, cycloalkyl, etc.; R7 = pyridinyl or Ph (wherein pyridinyl or Ph is optionally substituted by halo, CN, CF₃, etc.); R10 = Q1; R1, R4 = H, alkyl, OH, etc.; R2 = H, OH, O-alkyl, etc.; R3 = aryl or heteroaryl (wherein said moieties are optionally substituted by halo, CN, CF₃, etc.); R5 = H or alkyl; R1, R4 and R5 are not all simultaneously H.; when R1 is Me and R4 is H, then R5 is not Me.; when R4 is Me and R5 is H, then R1 is not Me.; when R5 is Me and R4 is H, then R1 is not Me.], pharmaceutically acceptable salts, hydrates, solvates, polymorphs, and prodrugs thereof were prepared For example, amidation of (3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid hydrochloride, e.g., prepared from (E)-2,4-difluorocinnamic acid in 3 steps, with (3S,4R)-3-methyl-4-phenylpiperidin-4-ol followed by treatment with HCl afforded compound II·HCl. Compds. according to the invention herein exhibited a binding constant at the MCR4 (melanocortin receptor 4) expressed as an K_i value against AGRP (agouti related protein) lower than 1000 nM. Compds. I are claimed useful for the treatment of sexual dysfunction and obesity.

RE.CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L6 ANSWER 4 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2007:14419 CAPLUS

DN 146:121832

TI Preparation of pyrrolidinylcarbonylpiperidine derivative as MC4R agonist and of crystalline forms of said derivative

IN Calabria, Ralph; Cheng, Yu; Ferlita, Russell R.; Kamali, Ashkan; Murry, Jerry A.; Mathre, David; Peresypkin, Andrey V.; Thompson, Karen; Wang, Jian; Wenslow, Robert M.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 50pp.

CODEN: PIXXD2

DT Patent



LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2007002462	A2	20070104	WO 2006-US24573	20060623
	WO 2007002462	A3	20070614		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RS, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW			
	RW:	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA			

PRAI US 2005-694488P P 20050627

GI



AB The present invention relates to a process for producing N-((1S)-1-[2-(1-((3S,4R)-1-tert-butyl-4-(2,4-difluorophenyl)pyrrolidin-3-yl)carbonyl)piperidin-4-yl]-5-chlorophenyl)ethyl)acetamide (I), and novel crystalline salts, hydrates, solvates, and polymorphic forms thereof. Thus, treatment of pyrrolidinecarboxylic acid II with CDI in acetonitrile, followed by reaction with piperidine derivative III in acetonitrile in the presence of triethylamine gave, after workup, I (free base). A solution of I (free base) in iso-Pr acetate was mixed with 0.5 N HCl/H₂O solution to give, after workup and crystallization, the crystalline hydrate mono-HCl salt of I.

L6 ANSWER 5 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:1256650 CAPLUS

DN 146:33047

TI Combination therapy for the treatment of obesity

IN Macneil, Tanya; Macneil, Douglas J.

PA USA

SO U.S. Pat. Appl. Publ., 21pp.

CODEN: USXXCO

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	US 20060270650	A1	20061130	US 2006-429721	20060508
PRAI	US 2005-684704P	P	20050526		

AB The present invention relates to compns. comprising calcium and/or xanthan gum and an anti-obesity agent, useful for the treatment and prevention of diabetes, obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. The present invention further provides for pharmaceutical compns., medicaments, and kits useful in carrying out these methods.

L6 ANSWER 6 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:365172 CAPLUS

DN 144:382018

TI Methods for the treatment of substance abuse and addiction

IN Bristow, Linda; Fong, Tung M.; Morse, Andrew C.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 63 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----

PI WO 2006041769 A2 20060420 WO 2005-US35449 20050930
 WO 2006041769 A3 20070614
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,
 LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,
 NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,
 SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,
 YU, ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM, AP, EA, EP, OA
 EP 1804798 A2 20070711 EP 2005-812168 20050930
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU
 US 20080021067 A1 20080124 US 2007-662018 20070305
 PRAI US 2004-616064P P 20041005
 WO 2005-US35449 W 20050930

OS MARPAT 144:382018

AB The present invention relates to methods of treating and preventing
 substance addiction and substance abuse, including nicotine addiction and
 nicotine addiction-related disorders in a subject comprising administering
 a melanocortin 4 receptor agonist to said subject. The present invention
 further relates to methods of treating or preventing substance addiction
 and substance addiction-related disorders in a subject comprising
 administering a melanocortin 4 receptor agonist to said subject. The
 present invention further provides for pharmaceutical compns. and
 medicaments useful in carrying out these methods.

L6 ANSWER 7 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:317218 CAPLUS

DN 144:363116

TI Combination therapy comprising PYY agonists for the treatment of obesity

IN Amatruda, John M.; Daruwala, Paul; Erond, Ngozi E.; Macneil, Douglas J.;
 Moller, David E.; Qian, Su

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 99 pp.

CODEN: PIXXD2


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006036770	A2	20060406	WO 2005-US34096	20050922
	WO 2006036770	A3	20060817		
	W:				
	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,				
	CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,				
	GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ,				
	LC, LK, LR, LS, LT, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MZ,				
	NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG,				
	SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN,				
	YU, ZA, ZM, ZW				
	RW:				
	AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,				
	IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,				
	CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,				
	GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,				
	KG, KZ, MD, RU, TJ, TM				
	AU 2005289710	A1	20060406	AU 2005-289710	20050922

CA 2577821	A1	20060406	CA 2005-2577821	20050922
EP 1799241	A2	20070627	EP 2005-803387	20050922
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101027075	A	20070829	CN 2005-80032222	20050922
US 20080064632	A1	20080313	US 2007-661960	20070302
IN 2007CN01330	A	20070831	IN 2007-CN1330	20070330
PRAI US 2004-612657P	P	20040924		
WO 2005-US34096	W	20050922		
OS MARPAT 144:363116				
GI				



AB The present invention relates to compns. comprising PYY, PYY3-36, or a PYY agonist, and an anti-obesity agent, useful for the treatment and prevention of obesity and obesity-related disorders. The present invention further relates to methods of treating or preventing obesity and obesity-related disorder in a subject in need thereof by administering a composition of the present invention. One example is a in vivo study of the effect of PYY3-36 on 4 h and 16 h food intake and body weight gain in mice and another example is an in vivo study of the effect of the combination of PYY3-36 and CB-1 inverse agonist AM-251 (I) on food intake and body weight in mice.

L6 ANSWER 8 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2006:236714 CAPLUS

DN 144:287793

TI Inhibition of voluntary ethanol consumption with non-peptidyl melanocortin 4-receptor agonists

IN Bristow, Linda; Fong, Tung M.; Morse, Andrew C.; Ren, Kunkun

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 60 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2006028631	A2	20060316	WO 2005-US28128	20050809
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU,				

ZA, ZM, ZW
 RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ,
 CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH,
 GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
 KG, KZ, MD, RU, TJ, TM
 EP 1781283 A2 20070509 EP 2005-812403 20050809
 R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE,
 IS, IT, LI, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, AL,
 BA, HR, MK, YU
 US 20080085885 A1 20080410 US 2007-660117 20070212
 PRAI US 2004-601486P P 20040813
 WO 2005-US28128 W 20050809
 OS MARPAT 144:287793
 AB The present invention relates to methods of inhibiting or reducing
 voluntary alc. consumption in a subject comprising administering a
 non-peptidyl melanocortin 4 receptor agonist to said subject. The present
 invention further relates to methods of treating or preventing alcoholism,
 alc. abuse, and alc. related disorders in a subject comprising
 administering a non-peptidyl melanocortin 4 receptor agonist to said
 subject. The present invention further provides for pharmaceutical
 compns. and medicaments useful in carrying out these methods.

 L6 ANSWER 9 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2006:165649 CAPLUS
 DN 144:232924
 TI Preparation of piperidine derivatives as melanocortin-4 receptor agonists
 IN Barakat, Khaled J.; Guo, Liangqin; Liu, Jian; Nargund, Ravi P.; Sebhat,
 Iyassu K.; Ye, Zhixiong
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 79 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	WO 2006019787	A2	20060223	WO 2005-US24806	20050713
	WO 2006019787	A3	20060914		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NG, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, LV, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG, BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
	AU 2005275232	A1	20060223	AU 2005-275232	20050713
	CA 2573714	A1	20060223	CA 2005-2573714	20050713
	EP 1773347	A2	20070418	EP 2005-769526	20050713
	CN 1984662	A	20070620	CN 2005-80024053	20050713
	JP 2008506696	T	20080306	JP 2007-521596	20050713
	IN 2006CN04795	A	20071005	IN 2006-CN4795	20061229
	US 20080051430	A1	20080228	US 2007-632001	20070109
PRAI	US 2004-588494P	P	20040716		
	WO 2005-US24806	W	20050713		
OS	MARPAT 144:232924				

GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB The title piperidine derivs. I [wherein m = 0-2; n = 1-2; R1 and R2 = independently halo, CF3, CH3, and OMe; R3 and R4 = independently halo, CF3, CN, alkyl, alkoxy, etc.; R5 = OH, halo, alkyl, alkoxy, etc.], or pharmaceutically acceptable salts thereof were prepared as agonists of the human melanocortin-4 receptors (MCR-4). For example, II was prepared in a multi-step synthesis. The title compds. showed IC50 less than 10 μ M against MCR-4. Formulations with finely divided lactose as hard gelatin capsule have been described. The compds. are useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MCR-4, such as obesity, diabetes, male or female sexual dysfunction.

L6 ANSWER 10 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2005:735328 CAPLUS

DN 143:211844

TI Preparation of Pyrrolidinyl(carbonyl) piperidines as melanocortin receptor 4 agonists for therapeutic use

IN Calabrese, Andrew Antony; Fradet, David Sebastien; Hepworth, David; Lansdell, Mark

PA Pfizer Inc, UK

SO U.S. Pat. Appl. Publ., 102 pp.

CODEN: USXXCO


DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI	US 20050176772	A1	20050811	US 2005-51144	20050203
	AU 2005213538	A1	20050825	AU 2005-213538	20050126
	CA 2555800	A1	20050825	CA 2005-2555800	20050126
	WO 2005077935	A1	20050825	WO 2005-IB208	20050126
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP	1716135	A1	20061102	EP 2005-702363	20050126
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, PL, SK, BA, HR, IS, YU				
CN	1930146	A	20070314	CN 2005-80007573	20050126
BR	2005007435	A	20070703	BR 2005-7435	20050126
JP	2007534668	T	20071129	JP 2006-551945	20050126
JP	4031814	B2	20080109		
NL	1028193	A1	20050808	NL 2005-1028193	20050204
NL	1028193	C2	20060420		
IN	2006DN04212	A	20070622	IN 2006-DN4212	20060721
MX	2006PA08934	A	20061002	MX 2006-PA8934	20060804

	NO 2006003944	A	20061031	NO 2006-3944	20060904
PRAI	GB 2004-2492	A	20040204		
	US 2004-543950P	P	20040212		
	GB 2004-12417	A	20040603		
	US 2004-580209P	P	20040615		
	GB 2004-25530	A	20041119		
	US 2004-634916P	P	20041210		
	WO 2005-IB208	W	20050126		
OS	MARPAT 143:211844				
GI					




AB The present invention relates to a class of melanocortin MCR4 agonists of general formula (I) wherein R1, R2, R3, R4 and R5 are as defined below and especially to selective MCR4 agonist compds., to their use in medicine, to compns. containing them, to processes for their preparation and to intermediates

used in such processes. The variables for I are: R1 = optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, aryl, alkylaryl, heterocycle, or alkylheterocycle; R2 is H, OH or OCH3; R3 = H, or optionally substituted alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, alkylcycloalkyl, aryl, alkylaryl, heterocycle, or alkylheterocycle; R4 = H, alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen, (CH2)pOR6, (CH2)pNR7R8, CN, C(O)R6, C(O)OR6, C(O)NR7R8, (CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 or OCH2CF3 wherein p=0, 1 or 2; R5 = alkyl, alkenyl, alkynyl, cycloalkyl, cycloalkenyl, halogen, (CH2)pOR6, (CH2)pNR7R8, CN, C(O)R6, C(O)OR6, C(O)NR7R8, (CH2)pNR7SO2R8, CF3, CH2CF3, OCF3 or OCH2CF3 wherein p=0, 1 or 2; or R4 and R5 form a fused ring; R6, R7 and R8 = H, CH3 or CH2CH3. Compds. of the present invention are particularly suitable for treating female sexual dysfunction, male erectile dysfunction, obesity and diabetes.

L6 ANSWER 11 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
AN 2005:99460 CAPLUS
DN 142:197886
TI Preparation of 4-aryl-1-(pyrrolidinylcarbonyl)piperidines as melanocortin-4 receptor agonists
IN Sings, Heather; Ujjainwalla, Feroze
PA Merck & Co., Inc., USA
SO PCT Int. Appl., 113 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	-----	-----	-----	-----

PI WO 2005009950 A2 20050203 WO 2004-US22911 20040716
 WO 2005009950 A3 20050602
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH,
 CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD,
 GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
 LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI,
 NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY,
 TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW
 RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM,
 AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK,
 EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PL, PT, RO, SE,
 SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 AU 2004259717 A1 20050203 AU 2004-259717 20040716
 CA 2532808 A1 20050203 CA 2004-2532808 20040716
 EP 1648457 A2 20060426 EP 2004-778422 20040716
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
 IE, SI, LT, LV, FI, RO, CY, TR, BG, CZ, EE, HU, PL, SK
 CN 1826116 A 20060830 CN 2004-80021119 20040716
 JP 2006528180 T 20061214 JP 2006-521142 20040716
 US 20060128963 A1 20060615 US 2005-560290 20051212
 IN 2006DN00517 A 20070810 IN 2006-DN517 20060131
 PRAI US 2003-489313P P 20030722
 WO 2004-US22911 W 20040716
 OS CASREACT 142:197886; MARPAT 142:197886
 GI



AB Title compds. [I; R1 = H, amidino, alkyliminoyl, alkyl, (CH₂)_nQ; n = 0-3;
 Q = (substituted) amino, cycloalkyl, Ph, naphthyl, heteroaryl; R2 =
 (substituted) Ph, naphthyl, heteroaryl; R3 = H, alkyl, halo, CF₃, CH₂CF₃,
 OCF₃, OCH₂CF₃, NO₂, OR₆, (substituted) (CH₂)_nQ₁; Q₁ = Ph, naphthyl,
 heteroaryl, heterocycloalkyl, cycloalkyl, amino, aminocarbonyl, cyano,
 etc.; R4 = (substituted) (CH₂)_nQ₃; Q₃ = NR₅NR₅R₆, NR₅R₉,
 NR₅CO(CH₂)_nCR₅[N(R₅)₂](CH₂)_qNR₅R₆, etc.; q = 0-4; R₅ = H, (substituted)
 alkyl, alkylcarbonyl; R₆ = R₅, (CH₂)_nQ₄; Q₄ = (substituted) cycloalkyl,
 heterocycloalkyl, Ph, naphthyl, heteroaryl, bicycloalkyl; R₉ = specified
 amino acid residue; Z = N, CR₁; p = 1, 2; m = 0-2], were claimed.
 Representative I bound to melanocortin-4 receptors with EC₅₀ = 10 μM.

L6 ANSWER 12 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 2004:80448 CAPLUS
 DN 140:122817
 TI NPY5 antagonist-antiobesity agent combination for the prevention and
 treatment of diabetes, obesity, and obesity-related disorders
 IN Macneil, Douglas J.; McIntyre, James H.; Van Der Ploeg, Leonardus H. T.;
 Ishihara, Akane
 PA Merck & Co., Inc., USA; Banyu Pharmaceutical Co., Ltd.
 SO PCT Int. Appl., 134 pp.

CODEN: PIXXD2

DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2004009015	A2	20040129	WO 2003-US22077	20030714
	WO 2004009015	A3	20040304		
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2492225	A1	20040129	CA 2003-2492225	20030714
	AU 2003253925	A1	20040209	AU 2003-253925	20030714
	EP 1534074	A2	20050601	EP 2003-765587	20030714
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
	JP 2005533849	T	20051110	JP 2004-523149	20030714
	US 20050288213	A1	20051229	US 2005-520566	20050107
PRAI	US 2002-396603P	P	20020718		
	US 2002-417999P	P	20021011		
	WO 2003-US22077	W	20030714		

OS MARPAT 140:122817

AB The invention discloses compns. comprising a NPY5 antagonist and an antiobesity agent, useful for the treatment and prevention of diabetes, obesity, and obesity-related disorders. The invention also discloses methods of treating or preventing obesity and obesity-related disorders in a subject in need thereof by administering a composition of the invention. The invention further discloses pharmaceutical compns., medicaments, and kits useful in carrying out the methods.

L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2003:737505 CAPLUS

DN 139:255308

TI Agouti-related protein as biomarker for efficacy of appetite suppressant drugs

IN Fong, Tung M.; Shen, Chun-Pyn; Van der Ploeg, Leonardus H. T.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 36 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2003075742	A2	20030918	WO 2003-US6437	20030303
	WO 2003075742	A3	20040401		
	W: CA, JP, US				
	RW: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR				
	CA 2477614	A1	20030918	CA 2003-2477614	20030303
	EP 1483580	A2	20041208	EP 2003-711370	20030303
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, RO, CY, TR, BG, CZ, EE, HU, SK				
	US 20050169839	A1	20050804	US 2004-506577	20040902

PRAI US 2002-361806P P 20020305
WO 2003-US6437 W 20030303

AB The present invention relates to agouti-related protein (AGRP) as a biomarker for the efficacy of appetite suppressant drugs given to humans or other mammals for the treatment of obesity. It further relates to a novel method of determining the efficacy of a test compound given to a subject for

the treatment of obesity, wherein the test compound is an appetite suppressant which does not stimulate the release of serotonin. It also relates to a method for following the progress of a therapeutic regime designed to alleviate obesity and to a method for determining the appropriate dosage of an appetite suppressant given to a subject for the treatment of obesity. Plasma levels of AGRP in lean rats were measured by RIA after treatment with various appetite suppressants. AGRP plasma levels were reduced by AM251, a cannabinoid CB1 inverse agonist, and by sibutramine.

L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

AN 2002:675993 CAPLUS

DN 137:216874

TI Acylated piperidine derivatives, specifically 1-(pyrrolidinylcarbonyl)piperidines, 1-(piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists, and their pharmaceutical compositions and therapeutic uses

IN Ujjainwalla, Feroze; Chu, Lin; Goulet, Mark T.; Lee, Bonnie; Warner, Daniel; Wyvratt, Matthew J.

PA Merck & Co., Inc., USA

SO PCT Int. Appl., 112 pp.

CODEN: PIXXD2

DT Patent

LA English

FAN.CNT 2

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	----	-----	-----	-----
PI	WO 2002068388	A2	20020906	WO 2002-US5724	20020225
	WO 2002068388	A3	20030313		
	W:	AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW			
	RW:	GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG			
	CA 2439152	A1	20020906	CA 2002-2439152	20020225
	AU 2002258414	A1	20020912	AU 2002-258414	20020225
	EE 200300415	A	20031215	EE 2003-415	20020225
	EP 1383501	A2	20040128	EP 2002-728357	20020225
	EP 1383501	B1	20070404		
	R:	AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR			
	HU 2003003376	A2	20040128	HU 2003-3376	20020225
	HU 2003003376	A3	20070828		
	JP 2004529105	T	20040924	JP 2002-567902	20020225
	NZ 527364	A	20041224	NZ 2002-527364	20020225
	CN 1633297	A	20050629	CN 2002-805674	20020225
	BR 2002007658	A	20051025	BR 2002-7658	20020225
	AT 358481	T	20070415	AT 2002-728357	20020225
	ES 2283550	T3	20071101	ES 2002-728357	20020225
	US 20030225060	A1	20031204	US 2003-356879	20030203
	US 6818658	B2	20041116		

	ZA 2003006160	A	20040721	ZA 2003-6160	20030808
	BG 108132	A	20041230	BG 2003-108132	20030825
	IN 2003CN01342	A	20051125	IN 2003-CN1342	20030826
	NO 2003003812	A	20031028	NO 2003-3812	20030827
	MX 2003PA07785	A	20031208	MX 2003-PA7785	20030827
	US 20040266821	A1	20041230	US 2004-894719	20040720
	IN 2007CN02320	A	20071012	IN 2007-CN2320	20070529
PRAI	US 2001-272258P	P	20010228		
	US 2001-300118P	P	20010622		
	WO 2002-US5724	W	20020225		
	US 2003-356897	A3	20030203		
	IN 2003-CN1342	A3	20030826		
OS	MARPAT 137:216874				
GI					




* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

AB Certain novel 4-substituted N-acylated piperidine derivs., specifically I, are agonists of the human melanocortin receptor(s) and, in particular, are selective agonists of the human melanocortin-4 receptor (MC-4R) [wherein: p = 1 or 2; q = 0, 1, or 2; n = 0, 1, or 2; R1 = H, amidino, alkyliminoyl, (un)substituted alkyl, (CH2)n-G1 [G1 = (un)substituted cycloalkyl, Ph, naphthyl, or heteroaryl]; R2 = (un)substituted Ph, naphthyl, or heteroaryl; X = alkyl, (CH2)n-G2 [G2 = (un)substituted cycloalkyl, Ph, naphthyl, heteroaryl, heterocyclyl, cyano, CONH2, CO2H, OH, NH2, and various derivs.] where any of (CH2)n may also be substituted; including pharmaceutically acceptable salts]. They are therefore useful for the treatment, control, or prevention of diseases and disorders responsive to the activation of MC-4R, such as obesity, diabetes, sexual dysfunction, including erectile dysfunction and female sexual dysfunction. Approx. 180 invention compds. I and approx. 25 intermediates were prepared For instance, (2-bromo-5-chlorophenyl)acetic acid underwent a sequence of Me esterification, coupling with tert-Bu 4-[[trifluoromethyl)sulfonyl]oxy]-3,6-dihydropyridine-1(2H)-carboxylate via a boronate ester, removal of the BOC group, and amidation with (3S,4R)-1-(tert-butyl)-4-(2,4-difluorophenyl)pyrrolidine-3-carboxylic acid. The unsatd. amide-ester underwent hydrogenation, saponification of the ester, and amidation with MeNH2.HCl, to give title compound II. Representative compds. I bound to cloned human MC-4R in vitro with IC50 values generally below 2 μ M, and also acted as agonists toward cloned human MCR in a functional assay with EC50 values less than 1 μ M.

L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN
 AN 1999:172595 CAPLUS
 DN 130:223167
 TI Preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity
 IN Budhu, Richard J.; Hale, Jeffrey J.; Holson, Edward; Lynch, Christopher; Maccoss, Malcolm; Mills, Sander G.; Berk, Scott C.; Willoughby, Christopher A.
 PA Merck & Co., Inc., USA
 SO PCT Int. Appl., 262 pp.
 CODEN: PIXXD2
 DT Patent
 LA English
 FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
-----	----	-----	-----	-----

PI WO 9909984 A1 19990304 WO 1998-US17755 19980827
 W: AL, AM, AU, AZ, BA, BB, BG, BR, BY, CA, CN, CU, CZ, EE, GE, HR,
 HU, ID, IL, IS, JP, KG, KR, KZ, LC, LK, LR, LT, LV, MD, MG, MK,
 MN, MX, NO, NZ, PL, RO, RU, SG, SI, SK, SL, TJ, TM, TR, TT, UA,
 US, UZ, VN, YU, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
 RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES,
 FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI,
 CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
 CA 2298813 A1 19990304 CA 1998-2298813 19980827
 AU 9892067 A 19990316 AU 1998-92067 19980827
 EP 1009405 A1 20000621 EP 1998-944548 19980827
 R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, PT, IE,
 SI, LT, LV, FI, RO
 US 6166037 A 20001226 US 1998-141227 19980827
 JP 2001526178 T 20011218 JP 2000-507374 19980827
 PRAI US 1997-57743P P 19970828
 GB 1998-1009 A 19980116
 WO 1998-US17755 W 19980827
 OS MARPAT 130:223167
 GI



AB Title modulators [I; R1 = CH2Ph, SO2Ph, CONHPh, H, CPh, (CH2)3Ph, 1-fluorencarbonyl, etc.; R = OH, H, Ph, CF3, CH2Ph, etc.; n = 0-2; S = S, C; R2 = benzo[d]azepin-3-yl, 4-phenyl-perhydroazepin-1-yl, etc.], pharmaceutically acceptable salts thereof, individual diastereomers, and enantiomers thereof are prepared as modulators of chemokine receptor activity. 21X19 combinatorial library was mentioned using com. available 4-sulfamylbenzoyl polystyrene resin supported subunits (21 pools) of trifluoromethylsulfonyl chloride, arylsulfonyl(carbonyl) chlorides, and heterocyclic sulfonyl(carbonyl) chlorides. Thus, compound II was prepared from Me (Z)-cinnamate and N-(methoxymethyl)-N-(trimethylsilylmethyl)benzylamine via seven steps.

RE.CNT 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d hitstr 13-15

L6 ANSWER 13 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN


IT 455956-46-4

RL: BSU (Biological study, unclassified); BIOL (Biological study)
(melanocortin receptor 4 agonist, plasma AGRP levels in lean rats after
treatment with; agouti-related protein as biomarker for efficacy of
appetite suppressant drugs)

RN 455956-46-4 CAPLUS

CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-
pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 14 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN


IT 455956-36-2P

RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic
preparation); THU (Therapeutic use); BIOL (Biological study); PREP
(Preparation); RACT (Reactant or reagent); USES (Uses)
(drug candidate; preparation of acylated piperidine derivs., particularly
(pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines,
and analogs, as melanocortin-4 receptor agonists)

RN 455956-36-2 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-
dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, methyl ester (CA
INDEX NAME)

Absolute stereochemistry.



IT 455955-95-0P 455955-96-1P 455955-97-2P

455955-98-3P 455955-99-4P 455956-00-0P
455956-01-1P 455956-02-2P 455956-03-3P
455956-04-4P 455956-05-5P 455956-06-6P
455956-07-7P 455956-08-8P 455956-09-9P
455956-10-2P 455956-11-3P 455956-12-4P
455956-13-5P 455956-14-6P 455956-15-7P
455956-16-8P 455956-17-9P 455956-18-0P
455956-19-1P 455956-20-4P 455956-21-5P
455956-22-6P 455956-23-7P 455956-24-8P
455956-25-9P 455956-26-0P 455956-27-1P
455956-28-2P 455956-29-3P 455956-30-6P
455956-31-7P 455956-32-8P 455956-33-9P
455956-34-0P 455956-35-1P 455956-37-3P
455956-38-4P 455956-39-5P 455956-40-8P
455956-41-9P 455956-42-0P 455956-43-1P
455956-44-2P 455956-45-3P 455956-46-4P
455956-47-5P 455956-48-6P 455956-49-7P
455956-50-0P 455956-51-1P 455956-52-2P
455956-53-3P 455956-54-4P 455956-55-5P
455956-56-6P 455956-57-7P 455956-58-8P
455956-59-9P 455956-60-2P 455956-61-3P
455956-62-4P 455956-63-5P 455956-64-6P
455956-65-7P 455956-66-8P 455956-67-9P
455956-68-0P 455956-69-1P 455956-70-4P
455956-71-5P 455956-72-6P 455956-73-7P
455956-74-8P 455956-75-9P 455956-76-0P
455956-77-1P 455956-78-2P 455956-79-3P
455956-80-6P 455956-81-7P 455956-82-8P
455956-83-9P 455956-84-0P 455956-85-1P
455956-86-2P 455956-87-3P 455956-88-4P
455956-89-5P 455956-90-8P 455956-91-9P
455956-92-0P 455956-93-1P 455956-94-2P
455956-95-3P 455956-96-4P 455956-97-5P
455956-98-6P 455956-99-7P 455957-00-3P
455957-01-4P 455957-02-5P 455957-03-6P
455957-04-7P 455957-05-8P 455957-06-9P
455957-07-0P 455957-08-1P 455957-09-2P
455957-10-5P 455957-11-6P 455957-12-7P
455957-13-8P 455957-14-9P 455957-15-0P
455957-16-1P 455957-17-2P 455957-18-3P
455957-19-4P 455957-20-7P 455957-21-8P
455957-22-9P 455957-23-0P 455957-24-1P
455957-25-2P 455957-26-3P 455957-27-4P
455957-28-5P 455957-29-6P 455957-30-9P
455957-31-0P 455957-32-1P 455957-33-2P
455957-34-3P 455957-35-4P 455957-36-5P
455957-37-6P 455957-38-7P 455957-39-8P
455957-40-1P 455957-41-2P 455957-42-3P
455957-43-4P 455957-44-5P 455957-45-6P
455957-46-7P 455957-47-8P 455957-48-9P
455957-49-0P 455957-50-3P 455957-51-4P
455957-52-5P 455957-53-6P 455957-54-7P
455957-55-8P 455957-56-9P 455957-57-0P
455957-58-1P 455957-59-2P 455957-60-5P
455957-61-6P 455957-65-0P 455957-66-1P
455957-67-2P 455957-68-3P 455957-69-4P
455957-70-7P 455957-71-8P 457068-69-8P

RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU
(Therapeutic use); BIOL (Biological study); PREP (Preparation); USES
(Uses)


(drug candidate; preparation of acylated piperidine derivs., particularly

(pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines,
and analogs, as melanocortin-4 receptor agonists)

RN 455955-95-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-96-1 CAPLUS

CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-97-2 CAPLUS

CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-98-3 CAPLUS

CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(1-pyrrolidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455955-99-4 CAPLUS

CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-00-0 CAPLUS

CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-(1-piperidinylcarbonyl)phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-01-1 CAPLUS

CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-02-2 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-03-3 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-04-4 CAPLUS

CN Piperidine, 4-[2-(1-azetidiny carbonyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-05-5 CAPLUS

CN Benzamide, 2-[1-[[1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-06-6 CAPLUS

CN Piperidine, 4-(2-cyano-4-fluorophenyl)-1-[[1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-07-7 CAPLUS

CN Benzamide, 5-chloro-2-[1-[[1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-08-8 CAPLUS

CN Benzamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-09-9 CAPLUS

CN Benzeneacetic acid, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-10-2 CAPLUS


CN Benzeneacetamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-11-3 CAPLUS
 CN Benzeneacetamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-12-4 CAPLUS
 CN Benzeneacetamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-13-5 CAPLUS
 CN Benzeneacetamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-14-6 CAPLUS

CN Benzeneacetamide, N-cyclobutyl-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-15-7 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-2-oxoethyl]phenyl]-1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-16-8 CAPLUS

CN Benzeneacetamide, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-17-9 CAPLUS

CN Benzeneacetamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-18-0 CAPLUS

CN Benzeneacetamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-19-1 CAPLUS

CN Benzeneacetamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-20-4 CAPLUS

CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 455956-21-5 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-22-6 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-23-7 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-24-8 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-25-9 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclopropyl-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-26-0 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclobutyl-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-27-1 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-28-2 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-29-3 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-30-6 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-31-7 CAPLUS


CN Piperidine, 4-[2-[2-(1-azetidiny)-2-oxoethyl]-4-chlorophenyl]-1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-32-8 CAPLUS
 CN Piperidine, 4-[4-chloro-2-[2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]-1-
 [[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-
 pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-33-9 CAPLUS
 CN Piperidine, 4-[4-chloro-2-[2-oxo-2-(1-piperidinyl)ethyl]phenyl]-1-
 [[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-
 pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-34-0 CAPLUS
 CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-
 dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-
 dimethylethyl)-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-35-1 CAPLUS

CN Benzoic acid, 5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-37-3 CAPLUS

CN Piperidine, 1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(dimethylamino)sulfonyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-38-4 CAPLUS

CN Benzamide, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4-fluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-39-5 CAPLUS

CN Benzoic acid, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-6-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-40-8 CAPLUS

CN Benzamide, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,6-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-41-9 CAPLUS

CN Benzamide, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N,6-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-42-0 CAPLUS

CN Benzoic acid, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-methyl-, ethyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-43-1 CAPLUS

CN Benzamide, 2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,5-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-44-2 CAPLUS


CN Benzoic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-45-3 CAPLUS
 CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,4-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-46-4 CAPLUS
 CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-47-5 CAPLUS
 CN Benzamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-48-6 CAPLUS

CN Benzamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-49-7 CAPLUS

CN Benzamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-50-0 CAPLUS

CN Benzamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-51-1 CAPLUS

CN Piperidine, 4-[2-(1-azetidinyldiphenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-chlorophenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-52-2 CAPLUS

CN Benzamide, 5-chloro-N-cyclopropyl-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-53-3 CAPLUS

CN Benzamide, 2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4,5-difluoro-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-54-4 CAPLUS

CN 7-Azabicyclo[2.2.1]heptane, 7-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorobenzoyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-55-5 CAPLUS

CN Benzamide, 2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl-5-(trifluoromethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-56-6 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny1)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-
[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-
pyrrolidiny1]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-57-7 CAPLUS


CN Piperidine, 4-[2-[2-(1-azetidiny1)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-
[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-
pyrrolidiny1]carbonyl]-, mono(trifluoroacetate) (9CI) (CA INDEX NAME)

CM 1

CRN 455956-56-6


CMF C32 H40 Cl F2 N3 O2

Absolute stereochemistry.




CM 2

CRN 76-05-1
CMF C2 H F3 O2




RN 455956-58-8 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N, α -dimethyl-
(CA INDEX NAME)

Absolute stereochemistry.




RN 455956-59-9 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl- α -methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-60-2 CAPLUS
CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- α -methyl-N-propyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-61-3 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl-N-(1-methylethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-62-4 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)-α-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-63-5 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclopropyl-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-64-6 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclobutyl-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-65-7 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclopentyl-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-66-8 CAPLUS

CN Benzeneacetamide, 5-chloro-N-cyclohexyl-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-

piperidinyl]- α -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-67-9 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N, α -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-68-0 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,N-diethyl- α -methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-69-1 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-ethyl-N, α -dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-70-4 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N,(1-methylethyl)-N, α -dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-71-5 CAPLUS

CN Benzeneacetamide, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-(1,1-dimethylethyl)-N, α -dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-72-6 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-methyl-2-oxo-2-(1-pyrrolidinyl)ethyl]phenyl]-

1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-73-7 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-methyl-2-oxo-2-(1-piperidinyl)ethyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-74-8 CAPLUS

CN 1-Propanone, 1-(1-azetidiny)-2-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-, (2S)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-75-9 CAPLUS

CN Piperidine, 4-[2-[(1R)-2-(1-azetidiny)-1-methyl-2-oxoethyl]-4-chlorophenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-76-0 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- α,α -dimethyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-77-1 CAPLUS

CN Benzeneacetic acid, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- α,α -dimethyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-78-2 CAPLUS

CN Benzeneacetamide, 2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N, α,α -trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-79-3 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-1,1-dimethyl-2-oxoethyl]-4-chlorophenyl]-1-[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-80-6 CAPLUS

CN Piperidine, 4-[2-[2-(1-azetidiny)-1,1-dimethyl-2-oxoethyl]-4-fluorophenyl]-1-[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-81-7 CAPLUS


CN Piperidine, 4-[2-[2-(1-azetidiny)-1,1-dimethyl-2-oxoethyl]phenyl]-1-[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidiny]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-82-8 CAPLUS
 CN Piperidine, 4-[2-[1-(1-azetidinylcarbonyl)cyclopropyl]-4-chlorophenyl]-1-
 [[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-
 pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-83-9 CAPLUS
 CN Cyclopropanecarboxamide, 1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-
 1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-N-
 methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-84-0 CAPLUS

CN Cyclopropanecarboxamide, 1-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-N,N-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-85-1 CAPLUS


CN Piperidine, 4-[4-chloro-2-(1-hydroxy-1-methylethyl)phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-86-2 CAPLUS
 CN Benzeneacetamide, 5-chloro-2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α,α-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-87-3 CAPLUS
 CN Benzeneacetamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-4-fluoro-N,α,α-trimethyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455956-88-4 CAPLUS
 CN Benzeneacetamide, 2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluoro-N-(2-hydroxyethyl)-N,α,α-trimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-89-5 CAPLUS

CN Morpholine, 4-[2-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-2-methyl-1-oxopropyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-90-8 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- α,α -dimethyl-, hydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-91-9 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- α,α -dimethyl-, 2-(1-methylethyl)hydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-92-0 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- α,α -dimethyl-, 2-acetylhydrazide (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-93-1 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-94-2 CAPLUS

CN Piperidine, 4-(2-aminophenyl)-1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-95-3 CAPLUS

CN Acetamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-96-4 CAPLUS

CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455956-97-5 CAPLUS


CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl-2-methyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-98-6 CAPLUS
 CN Propanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2,2-dimethyl- (CA INDEX NAME)

Absolute stereochemistry.




RN 455956-99-7 CAPLUS
 CN Cyclohexanecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-00-3 CAPLUS
 CN Butanamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-ethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-01-4 CAPLUS

CN Cyclopentanecarboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-02-5 CAPLUS

CN Cyclohexanecarboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-03-6 CAPLUS


CN Benzamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-04-7 CAPLUS
 CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(methanesulfonyl)amino]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-05-8 CAPLUS
 CN Piperidine, 4-[2-(aminomethyl)phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-06-9 CAPLUS
 CN Piperidine, 4-[2-[[[(diethylamino)carbonyl]amino]methyl]phenyl]-1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-07-0 CAPLUS

CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[methyl(1-methylethyl)amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-08-1 CAPLUS

CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[(methylamino)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-09-2 CAPLUS

CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[(dimethylamino)carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-10-5 CAPLUS

CN Piperidine, 1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[[(1,1-dimethylethyl)amino]carbonyl]amino]methyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-11-6 CAPLUS

CN Acetamide, N-[[2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-12-7 CAPLUS

CN Propanamide, N-[[2-[1-[[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-13-8 CAPLUS

CN Propanamide, N-[[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-14-9 CAPLUS

CN Propanamide, N-[[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]methyl]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-15-0 CAPLUS


CN Piperidine, 1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(4,4-dimethyl-2-oxo-3-oxazolidinyl)methyl]phenyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-16-1 CAPLUS
 CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[(2-oxo-3-oxazolidinyl)methyl]phenyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-17-2 CAPLUS
 CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[1-(2-oxo-3-oxazolidinyl)ethyl]phenyl]- (9CI)
 (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-18-3 CAPLUS
 CN Piperidine, 1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[2-[[(3,5-dimethyl-4-isoxazolyl)sulfonyl]amino]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-19-4 CAPLUS

CN 1,2,5-Oxadiazole-3-carboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-20-7 CAPLUS

CN 1,2,5-Thiadiazole-3-carboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-21-8 CAPLUS


CN 4-Oxazolecarboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-22-9 CAPLUS
 CN 5-Oxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-23-0 CAPLUS
 CN 1,3,4-Oxadiazole-2-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-5-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-24-1 CAPLUS
 CN 4-Isoxazolecarboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-25-2 CAPLUS

CN 1H-1,2,4-Triazole-3-carboxamide, N-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-5-methyl- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-26-3 CAPLUS

CN Piperidine, 4-[2-(1-aminoethyl)phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-27-4 CAPLUS

CN Piperidine, 4-[2-(1-aminoethyl)-4-chlorophenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-28-5 CAPLUS

CN Acetamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-29-6 CAPLUS

CN Acetamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-30-9 CAPLUS

CN Acetamide, N-[(1R)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-31-0 CAPLUS

CN Cyclobutanecarboxamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-32-1 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl)- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-33-2 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl)-2-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-34-3 CAPLUS

CN Propanamide, N-[1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-2,2-dimethyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-35-4 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-[[(methylamino)carbonyl]amino]ethyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-36-5 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-[[[(1,1-dimethylethyl)amino]carbonyl]amino]ethyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-37-6 CAPLUS

CN Acetamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-38-7 CAPLUS

CN Acetamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-39-8 CAPLUS


CN Piperidine, 4-[4-chloro-2-(5-oxo-3-pyrrolidinyl)phenyl]-1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-40-1 CAPLUS
 CN Piperidine, 4-[4-chloro-2-(5-oxo-2-pyrrolidinyl)phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 455957-41-2 CAPLUS
 CN Acetamide, N-[1-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]-N-methyl- (CA INDEX NAME)

Absolute stereochemistry.



RN 455957-42-3 CAPLUS
 CN Acetamide, N-[1-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-(trifluoromethyl)phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-43-4 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]propyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-44-5 CAPLUS

CN Acetamide, N-[(1S)-1-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-ethylphenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-45-6 CAPLUS

CN Piperidine, 4-[2-[(1S)-1-aminoethyl]-4-chlorophenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-46-7 CAPLUS

CN 1,3,4-Oxadiazole-2-carboxamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-5-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-47-8 CAPLUS

CN 5-Thiazolecarboxamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-48-9 CAPLUS

CN 1H-Imidazole-2-carboxamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-1-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-49-0 CAPLUS

CN 5-Pyrimidinecarboxamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-50-3 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-2-methylpropyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-51-4 CAPLUS

CN Piperidine, 4-[4-chloro-2-[1-(methylamino)ethyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-52-5 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(2S)-5-oxo-2-pyrrolidinyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-53-6 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(2R)-5-oxo-2-pyrrolidinyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-54-7 CAPLUS

CN Piperidine, 4-[4-chloro-2-(2-oxo-5-oxazolidinyl)phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-55-8 CAPLUS

CN Piperidine, 4-[4-chloro-2-(6-oxo-2-piperidinyl)phenyl]-1-[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-56-9 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(3R)-2-oxo-3-pyrrolidinyl]phenyl]-1-[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-57-0 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(3S)-2-oxo-3-pyrrolidinyl]phenyl]-1-[[(3S, 4R)-4-(2, 4-difluorophenyl)-1-(1, 1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-58-1 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(4R)-2-oxo-4-oxazolidinyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-59-2 CAPLUS

CN Piperidine, 4-[4-chloro-2-[(4S)-2-oxo-4-oxazolidinyl]phenyl]-1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI)
(CA INDEX NAME)


Absolute stereochemistry.



RN 455957-60-5 CAPLUS

CN Acetamide, N-[1-((1R)-1-[2-[1-[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl)ethyl]-5-fluorophenyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-61-6 CAPLUS

CN Acetamide, N-[(1S)-1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-65-0 CAPLUS

CN Benzamide, 5-chloro-2-[1-[(3R,4S)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-N-methyl- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-66-1 CAPLUS

CN Piperidine, 4-[2-[1-(1-azetidinyldimethylcarbamoyl)cyclopropyl]-4-fluorophenyl]-1-[[3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-67-2 CAPLUS

CN Acetamide, N-[1-[5-chloro-2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]-1-methylethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-68-3 CAPLUS

CN Piperidine, 1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-[4-fluoro-2-[1-[[(methylamino)carbonyl]amino]ethyl]phenyl]- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-69-4 CAPLUS

CN Cyclobutanecarboxamide, N-[1-[2-[1-[[(3S, 4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-70-7 CAPLUS

CN Propanamide, N-[1-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-5-fluorophenyl]ethyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-71-8 CAPLUS

CN Acetamide, N-[(1S)-1-[5-chloro-2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]ethyl]-, hydrochloride (1:1) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 457068-69-8 CAPLUS

CN Bicyclo[2.2.1]heptane-2-carboxamide, N-[2-[1-[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]phenyl]- (CA INDEX NAME)

Absolute stereochemistry.



IT 455957-79-6P 455957-80-9P 455957-84-3P

455957-85-4P 455957-86-5P


RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(intermediate; preparation of acylated piperidine derivs., particularly (pyrrolidinylcarbonyl)piperidines, (piperidinylcarbonyl)piperidines, and analogs, as melanocortin-4 receptor agonists)

RN 455957-79-6 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-80-9 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]- (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-84-3 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-1,2,3,6-tetrahydro-4-pyridinyl]-α-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-85-4 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl-, methyl ester (CA INDEX NAME)


Absolute stereochemistry.



RN 455957-86-5 CAPLUS

CN Benzeneacetic acid, 5-chloro-2-[1-[[[(3S,4R)-4-(2,4-difluorophenyl)-1-(1,1-dimethylethyl)-3-pyrrolidinyl]carbonyl]-4-piperidinyl]-α-methyl- (CA INDEX NAME)

Absolute stereochemistry.



L6 ANSWER 15 OF 15 CAPLUS COPYRIGHT 2008 ACS on STN

IT 221142-59-2P


RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); BIOL (Biological study); PREP (Preparation)

(preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity)

RN 221142-59-2 CAPLUS

CN Piperidine, 4-phenyl-1-[[[(3R,4S)-4-phenyl-1-(phenylmethyl)-3-pyrrolidinyl]carbonyl]-, rel- (9CI) (CA INDEX NAME)

Relative stereochemistry.



IT 221141-75-9P

RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)

(preparation of piperidinylpyrrolidins as modulators of chemokine receptor activity)

RN 221141-75-9 CAPLUS

CN 1-Piperidinecarboxylic acid, 4-phenyl-3-[(4-phenyl-1-piperidinyl)carbonyl]-, 1,1-dimethylethyl ester (CA INDEX NAME)

